Cytokinetics (CYTK) announced that COMET-HF, a confirmatory Phase 3 clinical trial of omecamtiv mecarbil in patients with symptomatic heart failure with severely reduced ejection fraction, is open to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results